Prevalence of fibrosis and steatosis determined by transition elastography and controlled attenuation parameter (fibroscanâ) in diabetic patients

Burak-Leipuner, A; García-Gorrosquieta, F; Uribe-Rivera, N; Servín-Caamaño, A; Romero-Bermúdez, JA; Ceceña-Martínez, LE; Alagón-Fernández del Campo, P; Vargas-Duran, FY; Soto-Martinez, AK; Hinojosa-Segura, CI; Montemira-Orozco, D; Perez-Hernández, JL; Alexanderson-Rosas, G; Higuera-de la Tijera, F

doi:10.1016/j.aohep.2022.100789

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Web of Science, Medline/PubMed, DOAJ and Conacyt

A Burak-Leipuner1, F García-Gorrosquieta1, N Uribe-Rivera1, A Servín-Caamaño2, JA Romero-Bermúdez2, LE Ceceña-Martínez2, P Alagón-Fernández del Campo1, FY Vargas-Duran1, AK Soto-Martinez1, CI Hinojosa-Segura1, D Montemira-Orozco1, JL Perez-Hernández1, G Alexanderson-Rosas2, F Higuera-de la Tijera1

1 Gastroenterology and hepatology. General Hospital of Mexico “Dr. Eduardo Liceaga. Mexico City, Mexico

2 Internal Medicine Services. General Hospital of Mexico “Dr. Eduardo Liceaga. Mexico City, Mexico

This item has received

224 Visits

Under a Creative Commons license

Article information

Abstract

Download PDF

Statistics

Special issue

This article is part of special issue:

Vol. 27. Issue S3

Abstracts from XVII Mexican Congress of Hepatology

More info

Introduction and Objective

Younossi ZM et al.have recently reported a higher prevalence of fatty liver disease associated with metabolic dysfunction (MAFLD) in diabetics (55.5%) versus the general population (25%); however, in Mexico, the prevalence of steatosis and fibrosis related to MAFLD in patients with type 2 diabetes (DM2) is not precisely known. This study aimed to determine the prevalence of hepatic fibrosis and steatosis by transition elastography and controlled attenuation parameter (CAP) using the FibroScanâ equipment in patients with DM2.

Materials and Methods

Observational, descriptive, transversal study included patients who attended the outpatient clinic for DM2 diagnosis between August- 2018 and May- 2022 and who underwent FibroScanâ to determine the absence/presence and degree of fibrosis and steatosis. The following were excluded: patients with risky alcohol consumption, Hepatitis B/C, any type of liver disease or previously diagnosed cirrhosis, and consumption of additional drugs to those for MS. Descriptive statistics were used and the prevalence of steatosis and fibrosis determined by Fibroscanâ was estimated.

Results

183 patients, 64.3% women, mean age 56.1±10.2 years. According to BMI, 81.4% were also overweight/obese (36.6% overweight, 27.2% grade-I obesity, 12.2% grade-II obesity, and 5.4% grade-III obesity). 53.8% also met the criteria for MS. 71.3% had glycosylated hemoglobin, of which 41.6% were out of the target (HbA1c >7.0). Regarding the degree of fibrosis, we found: F4= 29.1%, F3= 6.9%, F2= 4.6%, F1= 2.3% and F0= 57.1%. Regarding the steatosis degree, we found: S3= 23.4%, S2=18.3%, S1=11.7% and S0= 9.7%. Regarding adherence to treatment, we found poor adherence in 39.0%, good adherence in 61.0% and 6.5% of patients were not determined.

Conclusions

The prevalence of steatosis and fibrosis associated with MAFLD is high in Mexican diabetic patients.

Funding

The resources used in this study were from the hospital without any additional financing

Declaration of interest

The authors declare no potential conflicts of interest.

Full text is only aviable in PDF